1. What's New in NOACs in AF?

3. Introduction

4. GARFIELD-AF Registry: Variations in Use of NOAC Therapy Worldwide

5. GARFIELD-AF Registry: Mortality

6. GARFIELD-AF Registry: Examining Patient History

7. GARFIELD-AF Registry: Implications of Wrong Dose Treatment After 2 Years of Enrollment

8. GARFIELD-AF Registry: Discontinuation of NOACs

9. GARFIELD-AF Registry: Ramifications of Inadequate Anticoagulant Treatment

10. GARFIELD-AF Registry: Ramifications of Inadequate Anticoagulant Treatment (cont)

11. But First: The Endpoints

12. Rivaroxaban vs Warfarin Observational Study

13. Endpoints

14. Patient Demographics

15. Study Outcomes

16. Rivaroxaban: A Look at Dosing

17. Examination of Subgroup Analysis: Major Bleeding

18. Examination of Subgroup Analysis: MACE and MALE

19. Real-World Data vs Clinical Trial Data

20. Challenge of Comorbidities

21. AFIRE Study*

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)